Quick Answer
GT Biopharma, Inc. reported Cash And Cash Equivalents At Carrying Value of $6.81 million for the year ending 2025.
- GT Biopharma, Inc. showed an increase of +72.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from GT Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2009 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2013: $0.00 | Q1 2014: $4.0 thousand | Q2 2014: $1.0 thousand | Q3 2014: $664.0 thousand | Q1 2015: $1.42 million | Q2 2015: $125.0 thousand | Q3 2015: $42.0 thousand | Q1 2016: $30.0 thousand | Q2 2016: $355.0 thousand | Q3 2016: $154.0 thousand | Q1 2017: $235.0 thousand | Q2 2017: $39.0 thousand | Q3 2017: $2.73 million | Q1 2018: $2.87 million | Q2 2018: $1.10 million | Q3 2018: $1.23 million | Q1 2019: $51.0 thousand | Q2 2019: $264.0 thousand | Q3 2019: $313.0 thousand | Q1 2020: $5.0 thousand | Q2 2020: $851.0 thousand | Q3 2020: $350.0 thousand | Q4 2020: $5.30 million | Q1 2021: $27.56 million | Q1 2023: $2.05 million | Q2 2023: $2.77 million | Q3 2023: $2.65 million | Q1 2024: $1.95 million | Q2 2024: $9.25 million | Q3 2024: $6.42 million | Q1 2025: $2.37 million | Q2 2025: $5.23 million | Q3 2025: $2.53 million.
- Over the full 18 years of available data (2009 to 2025), GT Biopharma, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 426.8%.
- Historical annual values: Fiscal year 2025: $6.81 million | Fiscal year 2024: $3.95 million | Fiscal year 2023: $1.08 million | Fiscal year 2022: $5.67 million | Fiscal year 2021: $8.97 million | Fiscal year 2020: $5.30 million | Fiscal year 2019: $28.0 thousand | Fiscal year 2018: $60.0 thousand | Fiscal year 2017: $576.0 thousand | Fiscal year 2016: $19.0 thousand | Fiscal year 2015: $47.0 thousand | Fiscal year 2014: $855.0 thousand | Fiscal year 2013: $43.0 thousand | Fiscal year 2012: $123.0 thousand | Fiscal year 2012: $61.0 thousand | Fiscal year 2011: $92.0 thousand | Fiscal year 2010: $54.0 thousand | Fiscal year 2009: $1.29 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: